Get startedLog in
    Picture of Quest Diagnostics logo

    DGX — Quest Diagnostics News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareConservativeLarge CapHigh Flyer
    All News

    Brief: Mass General Brigham Launches Two Trials Using Haystack MRD ctDNA to Guide Post-Surgery Cancer Treatment

    Picture of Quest Diagnostics logoQuest Diagnostics
    07/08/2025 14:21
    Aug 7 (Reuters) - Quest Diagnostics Inc DGX.N:

MASS GENERAL BRIGHAM LAUNCHES TWO CLINICAL TRIALS TO STUDY HAYSTACK MRD CTDNA AS GUIDE FOR POST-SURGICAL TREATMENT FOR TWO CANCER TYPES

Source text: ID:nPn8fn612a

Further company coverage: DGX.N

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Quest Diagnostics

    See all news